Acute Lymphoblastic Leukemia PDX Models

Most commercially available blood cancer patient-derived xenograft (PDX) models are transient in nature, and non-transferable through passages (not renewable), without disease symptoms or mortality. However, CrownBio’s PDX models for blood cancer are permanent, and allow the study of disease recurrence after initial treatment challenge and the efficacy testing of novel agents against drug resistance. The CrownBio acute lymphoblastic leukemia (ALL) PDX collection covers a wide range including patient-relevant mutations e.g. BCR/ABL(+). More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBERCANCER SUBTYPE # per page
AL5503 BCLICK TO VIEW
AL5511 TCLICK TO VIEW
AL5514 BCLICK TO VIEW
AL5518 BCLICK TO VIEW
AL5521 BCLICK TO VIEW
AL7015 BCLICK TO VIEW
AL7119 BCLICK TO VIEW
AL7142 TCLICK TO VIEW
AL7155 BCLICK TO VIEW
AL7174 TCLICK TO VIEW
AL7267 BCLICK TO VIEW
AL7442 TCLICK TO VIEW
AL7443 BCLICK TO VIEW
AL7447 BCLICK TO VIEW
AL7473 TCLICK TO VIEW
AL7475 TCLICK TO VIEW
AL8156 BCLICK TO VIEW
AL8223 BCLICK TO VIEW